Philippe Gabríel Steg

198.1k total citations · 36 hit papers
1.1k papers, 77.2k citations indexed

About

Philippe Gabríel Steg is a scholar working on Cardiology and Cardiovascular Medicine, Surgery and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Philippe Gabríel Steg has authored 1.1k papers receiving a total of 77.2k indexed citations (citations by other indexed papers that have themselves been cited), including 865 papers in Cardiology and Cardiovascular Medicine, 467 papers in Surgery and 187 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Philippe Gabríel Steg's work include Acute Myocardial Infarction Research (402 papers), Antiplatelet Therapy and Cardiovascular Diseases (387 papers) and Coronary Interventions and Diagnostics (226 papers). Philippe Gabríel Steg is often cited by papers focused on Acute Myocardial Infarction Research (402 papers), Antiplatelet Therapy and Cardiovascular Diseases (387 papers) and Coronary Interventions and Diagnostics (226 papers). Philippe Gabríel Steg collaborates with scholars based in France, United States and United Kingdom. Philippe Gabríel Steg's co-authors include Deepak L. Bhatt, Andrzej Budaj, Lars Wallentin, Stefan James, Robert F. Storey, Kim A. Eagle, Keith A.A. Fox, Roberto Ferrari, Michał Tendera and Benjamin M. Scirica and has published in prestigious journals such as New England Journal of Medicine, The Lancet and JAMA.

In The Last Decade

Philippe Gabríel Steg

1.1k papers receiving 74.6k citations

Hit Papers

Ticagrelor versus Clopido... 2000 2026 2008 2017 2009 2007 2011 2013 2002 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
    2009 4.6k citations Lars Wallentin, Andrzej Budaj et al. New England Journal of Medicine profile →
  2. Clinical End Points in Coronary Stent Trials
    2007 4.2k citations Roxana Mehran, Philippe Gabríel Steg et al. Circulation profile →
  3. Standardized Bleeding Definitions for Cardiovascular Clinical Trials
    2011 2.9k citations Roxana Mehran, Deepak L. Bhatt et al. Circulation profile →
  4. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus
    2013 2.5k citations Deepak L. Bhatt, Philippe Gabríel Steg et al. New England Journal of Medicine profile →
  5. Rapid Measurement of B-Type Natriuretic Peptide in the Emergency Diagnosis of Heart Failure
    2002 2.4k citations Philippe Gabríel Steg et al. New England Journal of Medicine profile →
  6. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
    2018 2.0k citations Deepak L. Bhatt, Philippe Gabríel Steg et al. New England Journal of Medicine profile →
  7. Radial versus femoral access for coronary angiography and intervention in patients with acute coronary syndromes (RIVAL): a randomised, parallel group, multicentre trial
    2011 1.4k citations Andrzej Budaj, Philippe Gabríel Steg et al. profile →
  8. Genetic Determinants of Response to Clopidogrel and Cardiovascular Events
    2008 1.2k citations Tabassome Simon, Murielle Mary‐Krause et al. New England Journal of Medicine profile →
  9. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure
    2020 1.2k citations Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine profile →
  10. A Validated Prediction Model for All Forms of Acute Coronary Syndrome
    2004 1.2k citations Kim A. Eagle, Karen S. Pieper et al. JAMA profile →
  11. One-Year Cardiovascular Event Rates in Outpatients With Atherothrombosis
    2007 968 citations Philippe Gabríel Steg, Deepak L. Bhatt et al. JAMA profile →
  12. Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation
    2017 843 citations Christopher P. Cannon, Deepak L. Bhatt et al. New England Journal of Medicine profile →
  13. Resting Heart Rate in Cardiovascular Disease
    2007 805 citations Nicolas Danchin, Philippe Gabríel Steg et al. Journal of the American College of Cardiology profile →
  14. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease
    2020 789 citations Deepak L. Bhatt, Michael Szarek et al. New England Journal of Medicine profile →
  15. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial
    2008 736 citations Philippe Gabríel Steg et al. profile →
  16. Elevated Levels of Shed Membrane Microparticles With Procoagulant Potential in the Peripheral Circulating Blood of Patients With Acute Coronary Syndromes
    2000 726 citations Philippe Gabríel Steg et al. Circulation profile →
  17. Derivation and validation of the predicting bleeding complications in patients undergoing stent implantation and subsequent dual antiplatelet therapy (PRECISE-DAPT) score: a pooled analysis of individual-patient datasets from clinical trials
    2017 659 citations Stefan James, Philippe Gabríel Steg et al. profile →
  18. B-Type Natriuretic Peptide and Clinical Judgment in Emergency Diagnosis of Heart Failure
    2002 658 citations Philippe Gabríel Steg et al. Circulation profile →
  19. Decline in Rates of Death and Heart Failure in Acute Coronary Syndromes, 1999-2006
    2007 627 citations Keith A.A. Fox, Philippe Gabríel Steg et al. JAMA profile →
  20. A Cause for Concern
    2007 596 citations Philippe Gabríel Steg et al. Circulation profile →
  21. Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a subgroup analysis of a randomised controlled trial
    2008 593 citations Philippe Gabríel Steg et al. profile →
  22. Early versus Delayed Invasive Intervention in Acute Coronary Syndromes
    2009 582 citations Christopher B. Granger, Philippe Gabríel Steg et al. New England Journal of Medicine profile →
  23. Effect of CYP2C19 and ABCB1 single nucleotide polymorphisms on outcomes of treatment with ticagrelor versus clopidogrel for acute coronary syndromes: a genetic substudy of the PLATO trial
    2010 582 citations Lars Wallentin, Stefan James et al. profile →
  24. Heart Failure, Saxagliptin, and Diabetes Mellitus: Observations from the SAVOR-TIMI 53 Randomized Trial
    2014 545 citations Darren K. McGuire, Philippe Gabríel Steg et al. Circulation profile →
  25. Development and Validation of a Prediction Rule for Benefit and Harm of Dual Antiplatelet Therapy Beyond 1 Year After Percutaneous Coronary Intervention
    2016 544 citations Philippe Gabríel Steg et al. JAMA profile →
  26. Comparative Determinants of 4-Year Cardiovascular Event Rates in Stable Outpatients at Risk of or With Atherothrombosis
    2010 539 citations Deepak L. Bhatt, Kim A. Eagle et al. JAMA profile →
  27. Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry
    2012 505 citations Philippe Gabríel Steg, Jean‐Claude Tardif et al. European Heart Journal profile →
  28. Baseline characteristics, management practices, and in-hospital outcomes of patients hospitalized with acute coronary syndromes in the Global Registry of Acute Coronary Events (GRACE)**Further information about the project, along with a complete list of the study participants, can be found at www.outcomes.org/grace.
    2002 500 citations Philippe Gabríel Steg, Robert J. Goldberg et al. profile →
  29. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
    2010 436 citations Christopher P. Cannon, Robert A. Harrington et al. profile →
  30. One-Year Risk of Stroke after Transient Ischemic Attack or Minor Stroke
    2016 374 citations Julien Labreuche, Gregory W. Albers et al. New England Journal of Medicine profile →
  31. Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death
    2015 364 citations Philippe Gabríel Steg, Kim A. Eagle et al. Circulation profile →
  32. Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure
    2014 320 citations Philippe Gabríel Steg, Jean‐Claude Tardif et al. New England Journal of Medicine profile →
  33. Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study
    2016 298 citations Jean‐Claude Tardif, Deepak L. Bhatt et al. profile →
  34. Ticagrelor for Prevention of Ischemic Events After Myocardial Infarction in Patients With Peripheral Artery Disease
    2016 249 citations Marc P. Bonaca, Deepak L. Bhatt et al. Journal of the American College of Cardiology profile →
  35. ST-segment elevation myocardial infarction
    2019 234 citations Evangelos Giannitsis, Shinya Goto et al. profile →
  36. Ticagrelor in Patients with Stable Coronary Disease and Diabetes
    2019 204 citations Philippe Gabríel Steg, Deepak L. Bhatt et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Philippe Gabríel Steg France 123 56.5k 30.1k 10.3k 9.9k 9.8k 1.1k 77.2k
Eugene Braunwald United States 127 50.8k 0.9× 30.6k 1.0× 12.1k 1.2× 12.4k 1.3× 4.4k 0.4× 703 77.3k
Christopher P. Cannon United States 125 38.0k 0.7× 27.9k 0.9× 10.8k 1.0× 14.2k 1.4× 5.3k 0.5× 879 67.5k
Deepak L. Bhatt United States 142 57.5k 1.0× 40.1k 1.3× 7.9k 0.8× 23.5k 2.4× 14.4k 1.5× 2.0k 108.1k
Christopher B. Granger United States 119 49.5k 0.9× 13.8k 0.5× 10.0k 1.0× 4.1k 0.4× 4.8k 0.5× 846 63.9k
Eugene Braunwald United States 104 43.0k 0.8× 20.7k 0.7× 12.5k 1.2× 5.6k 0.6× 3.7k 0.4× 448 59.7k
Harvey D. White New Zealand 99 45.2k 0.8× 21.6k 0.7× 14.0k 1.4× 3.1k 0.3× 4.2k 0.4× 719 57.9k
Eric D. Peterson United States 142 46.9k 0.8× 21.4k 0.7× 8.0k 0.8× 5.2k 0.5× 9.8k 1.0× 1.2k 79.8k
Gregg C. Fonarow United States 157 79.0k 1.4× 17.6k 0.6× 6.7k 0.7× 10.1k 1.0× 14.1k 1.4× 1.8k 113.5k
Emelia J. Benjamin United States 141 70.6k 1.3× 11.9k 0.4× 9.6k 0.9× 8.4k 0.9× 9.5k 1.0× 788 102.0k
Sabina A. Murphy United States 97 30.0k 0.5× 17.9k 0.6× 6.4k 0.6× 8.1k 0.8× 2.7k 0.3× 487 43.5k

Countries citing papers authored by Philippe Gabríel Steg

Since Specialization
Citations

This map shows the geographic impact of Philippe Gabríel Steg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Philippe Gabríel Steg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Philippe Gabríel Steg more than expected).

Fields of papers citing papers by Philippe Gabríel Steg

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Philippe Gabríel Steg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Philippe Gabríel Steg. The network helps show where Philippe Gabríel Steg may publish in the future.

Co-authorship network of co-authors of Philippe Gabríel Steg

This figure shows the co-authorship network connecting the top 25 collaborators of Philippe Gabríel Steg. A scholar is included among the top collaborators of Philippe Gabríel Steg based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Philippe Gabríel Steg. Philippe Gabríel Steg is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gibson, C. Michael, Maria Cecilia Bahit, Roxana Mehran, et al.. (2025). Oral factor xia inhibitor milvexian after a recent acute coronary syndrome: Rationale and design of the phase 3 (Librexia ACS). American Heart Journal. 285. 21–28. 4 indexed citations
2.
Schwartz, Gregory G., Michael Szarek, J. Wouter Jukema, et al.. (2025). Risk of Incident Diabetes Related to Lipoprotein(a), LDL Cholesterol, and Their Changes With Alirocumab: Post Hoc Analyses of the ODYSSEY OUTCOMES Randomized Trial. Diabetes Care. 48(4). 596–604. 5 indexed citations
3.
Grave, Clémence, Christophe Bonaldi, Laure Carcaillon‐Bentata, et al.. (2024). Burden of Cardio-Cerebrovascular and Renal Diseases Attributable to Systolic Hypertension in France in 2021. Hypertension. 82(2). 357–369. 2 indexed citations
4.
Bhatt, Deepak L., Michael Miller, Eliot A. Brinton, et al.. (2024). Icosapent ethyl following acute coronary syndrome: the REDUCE-IT trial. European Heart Journal. 45(13). 1173–1176. 13 indexed citations
5.
Stone, Gregg W., Marco Valgimigli, David Erlinge, et al.. (2024). Bivalirudin vs Heparin Anticoagulation in STEMI. Journal of the American College of Cardiology. 84(16). 1512–1524. 6 indexed citations
6.
Lemesle, Gilles, Nicolas Lamblin, Guillaume Schurtz, et al.. (2024). Comparison of Incidence and Prognostic Impact of Ischemic, Major Bleeding and Heart Failure Events in Patients With Chronic Coronary Syndrome: Insights From the CORONOR Registry. Circulation. 149(22). 1708–1716. 4 indexed citations
7.
Goldenberg, Neil A., Sam Schulman, John M. Kittelson, et al.. (2024). Duration of anticoagulation for venous thromboembolism in pediatric patients: Evaluation of the Duration of Therapy for Thrombosis in Children (Kids-DOTT) trial outcomes at 2 years. Journal of Thrombosis and Haemostasis. 23(2). 651–656.
8.
Zeller, Marianne, Nicolas Danchin, Yves Cottin, et al.. (2023). Standard modifiable risk factors and mortality in patients with ST-segment elevation myocardial infarction: Findings from the FRENCHIE cohort. Archives of cardiovascular diseases. 117(1). S3–S4. 1 indexed citations
9.
Moriarty, Patrick M., Philippe Gabríel Steg, Jennifer McGinniss, et al.. (2022). Relation of red blood cell distribution width to risk of major adverse cardiovascular events, death, and effect of alirocumab after acute coronary syndromes. Journal of clinical lipidology. 16(5). 747–756. 2 indexed citations
10.
Spyropoulos, Alex C., Mark Goldin, Walter Ageno, et al.. (2022). Rivaroxaban Plus Aspirin for Extended Thromboprophylaxis in Acutely Ill Medical Patients: Insights from the MARINER Trial. SHILAP Revista de lepidopterología. 6(3). e177–e183. 1 indexed citations
11.
Ducrocq, Grégory, José Ramón González‐Juanatey, Étienne Puymirat, et al.. (2021). Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia. JAMA. 325(6). 552–552. 124 indexed citations
12.
Bhatt, Deepak L., Michael Szarek, Philippe Gabríel Steg, et al.. (2020). Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure. New England Journal of Medicine. 384(2). 117–128. 1204 indexed citations breakdown →
13.
14.
Bhatt, Deepak L., Philippe Gabríel Steg, Michael Miller, et al.. (2018). Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. New England Journal of Medicine. 380(1). 11–22. 2003 indexed citations breakdown →
15.
Boccara, Franck, Murielle Mary‐Krause, Sylvie Lang, et al.. (2016). Statin therapy and low-density lipoprotein cholesterol reduction in HIV-infected individuals after acute coronary syndrome: Results from the PACS-HIV lipids substudy. American Heart Journal. 183. 91–101. 18 indexed citations
16.
Ducrocq, Grégory, Phillip J. Schulte, Andrzej Budaj, et al.. (2015). Balancing the risk of ischaemic and bleeding events in ACS. European Heart Journal. 36. 860–861. 1 indexed citations
17.
Hansel, Boris, Ronan Roussel, Yedid Elbez, et al.. (2015). Cardiovascular risk in relation to body mass index and use of evidence-based preventive medications in patients with or at risk of atherothrombosis. European Heart Journal. 36(40). 2716–2728. 42 indexed citations
18.
Wallentin, Lars, Stefan James, Evangelos Giannitsis, et al.. (2012). Abstract 15929: Outcomes with Ticagrelor Versus Clopidogrel in Relation to High Sensitivity Troponin-T in Non-ST-Elevation Acute Coronary Syndrome Patients Managed with Early Invasive or Non-Invasive Treatment - A Substudy from the Prospective Randomized PLATelet Inhibition and Patient Outcomes (PLATO) Trial. Circulation. 126. 3 indexed citations
19.
Smolderen, Kim G., Lei Ye, Eyal Cohen, et al.. (2010). One-year costs associated with cardiovascular disease in Canada: Insights from the REACH registry. Canadian Journal of Cardiology. 26. 297–305. 1 indexed citations
20.
Spencer, Frederick A., Mauro Moscucci, Christopher B. Granger, et al.. (2007). Does Comorbidity Account for the Excess Mortality in Patients With Major Bleeding in Acute Myocardial Infarction?. Circulation. 116(24). 2793–2801. 180 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Christopher P. Cannon Breakdown of academic impact, for papers by Deepak L. Bhatt Breakdown of academic impact, for papers by Christopher B. Granger Breakdown of academic impact, for papers by Eugene Braunwald Breakdown of academic impact, for papers by Harvey D. White Breakdown of academic impact, for papers by Eric D. Peterson Breakdown of academic impact, for papers by Gregg C. Fonarow Breakdown of academic impact, for papers by Emelia J. Benjamin Breakdown of academic impact, for papers by Sabina A. Murphy
Rankless by CCL
2026